Tamibarotene: Leukemia therapy retinoid RARα agonist

Drugs of the Future

Volumn 30, Issue 7, 2005, Pages 688-693

  Davies, S L ^a   Castaner J ^a   Garcia Capdevila L ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2,3 (2,5 DIMETHYL 2,5 HEXANO) 5 METHYL 5H DIBENZO[B,E][1,4]DIAZEPIN 11 YL]BENZOIC ACID; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; BEXAROTENE; CARBON 14; DA 011; DIPHENYLAMINE DERIVATIVE; HX 620; HX 630; NSC 6080000; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR ALPHA AGONIST; TAMIBAROTENE; TOS 80; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL STRAIN HL 60; CHEILITIS; CHROMOSOME TRANSLOCATION 15; CLINICAL TRIAL; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRY LIP; DRY SKIN; GRANULOCYTE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLEUKOCYTOSIS; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; ISOTOPE LABELING; LEUKOCYTOSIS; LIP DISEASE; NONHUMAN; PROMYELOCYTE; PROMYELOCYTIC LEUKEMIA; REMISSION; RETINOIC ACID SYNDROME; XEROSIS;

EID: 27644442873     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.07.923254     Document Type: Article

References (32)

1. Shudo, K. Benzoic acid derivatives. EP 0170105, JP 1986022047, JP 1986076440, US 4703110.
2. McKenzie, S.B. Advances in understanding the biology and genetics of acute myelocytic leukemia. Clin Lab Sci 2005,18: 28-37.
3. Grimwade, D., Enver, T. Acute promyelocytic leukemia: Where does it stem from? Leukemia 2004, 18: 375-84.
4. Chauffaille, M.L., Figueiredo, M.S., Beltrani, R., Antunes, S.V., Yamamoto, M., Kerbauy, J. Acute promyelocytic leukemia: The study of t(15; 17) translocation by fluorescent in situ hybridization, reverse transcriptase- polymerase chain reaction and cytogenetic techniques. Braz J Med Biol Res 2001, 34: 735-43.
5. Ruiz-Argüelles, G.J., Garcés-Eisele, J., Reyes- Núñez, V., Gómez-Rangel, J.D., Ruiz-Delgado, G.J. More on geographic hematology: The breakpoint cluster regions of the PML/RARα fusion gene in Mexican Mestizo patients with promyelocytic leukemia are different from those in Caucasians. Leuk Lymphoma 2004, 45: 1365-8.
6. Lutz, P.G., Moog-Lutz, C., Cayre, Y.E. Signaling revisited in acute promyelocytic leukemia. Leukemia 2002, 16: 1933-9.
7. Tallman, M.S. Acute promyelocytic leukemia as a paradigm for targeted therapy. Semin Hematol 2004, 41(2, Suppl. 4): 27-32.
8. Jing, Y. The PML-RARα fusion protein and targeted therapy for acute promyelocytic leukemia. Leuk Lymphoma 2004, 45: 639-48.
9. Japanese launch of Amnolake for APL. DailyDrugNews.com (Daily Essentials) June 13, 2005.
10. Kagechika, H., Kawachi, E., Hashimoto, Y., Himi, T., Shudo, K. Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. J Med Chem 1988, 31: 2182-92.
11. Nagy, L., Thomàzy, V.A., Shipley, G.L., Fésüs, L., Lamph, W., Heyman, R.A., Chandraratna, R.A., Davies, P.J. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol Cell Biol 1995, 15: 3540-51.
12. Umemiya, H., Kawachi, E., Kagechika, H., Fukasawa, H., Hashimoto, Y., Shudo, K. Synergists for retinoid in cellular differentiation of human promyelocytic leukemia cells HL-60. Chem Pharm Bull 1995, 43: 1827-9.
13. Umemiya, H., Kagechika, H., Fukasawa, H. et al. Action mechanism of retinoid-synergistic dibenzodiazepines. Biochem Biophys Res Commun 1997, 233: 121-5.
14. Umemiya, H., Fukasawa, H., Ebisawa, M., Eyrolles, L., Kawachi, E., Eisenmann, G., Gronemeyer, H., Hashimoto, Y., Shudo, K., Kagechika, H. Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers. J Med Chem 1997, 40: 4222-34.
15. Ohta, K., Tsuji, M., Kawachi, E., Fukasawa, H., Hashimoto, Y., Shudo, K., Kagechika, H. Potent retinoid synergists with a diphenylamine skeleton. Biol Pharm Bull 1998, 21: 544-6.
16. Hara, M., Suzuki, S., Mori, J. et al. Thyroid hormone regulation of apoptosis induced by retinoic acid in promyeloleukemic HL-60 cells: Studies with retinoic acid receptor-specific and retinoid X receptor-specific ligands. Thyroid 2000, 10: 1023-34.
17. Schneider, S.M., Offterdinger, M., Huber, H., Grunt, T.W. Retinoic acid receptor-alpha is title main receptor that mediates the biological effects of retinoids in SK-BR-3 breast cancer cells. Proc Am Assoc Cancer Res (AACR) 2000, 41: Abst 1503.
18. Murakami, K., Matsuura, T., Hasumura, S., Nagamori, S., Yamada, Y., Saiki, I. Involvement of insulin-like growth factor binding protein-3 in the retinoic acid receptor-alpha-mediated inhibition of hepatocellular carcinoma cell proliferation. Cancer Lett. 2000, 151: 63-70.
19. Ishida, S., Shigemoto-Mogami, Y., Shinozaki, Y., Kagechika, H., Shudo, K., Ozawa, S., Sawada, J., Ohno, Y., Inoue, K. Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol 2004, 68: 2177-86.
20. Algate, D.R., Atterson, P.R., Beard, D.J., Doteuchi, M., Jobling, C.M., Munt, P.L. General pharmacology of new synthetic retinoid, 4-[(5,6,7,8- tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl]benzoic acid (Am-80) in experimental animals. Pharmacometrics 1994, 47: 451-63.
21. Hashimoto, S., Mizobuchi, M., Kuroda, T., Okabe, H., Mizojiri, K., Takahashi, S., Kikuchi, J., Terui, Y. Biotransformation of a new synthetic retinoid, 4-[(5,6,7, 8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid (Am-80), in the rat. Structure elucidation of the metabolites by mass and NMR spectrometry. Xenobiotica 1994, 24: 1177-93.
22. Mizojiri, K., Okabe, H., Sugeno, K., Esumi, Y., Takaichi, M., Miyake, T., Seki, H., Inaba, A. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl]benzoic acid. 1st Communication: Absorption, distribution, metabolism and excretion after topical application and subcutaneous administration in rats. Arzneim-Forsch Drug Res 1997, 47: 59-69.
23. Mizojiri, K., Okabe, H., Sugeno, K., Esumi, Y., Takaichi, M., Okamura, Y., Kashiwazaki, K., Takahashi, N. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl) carbamoyl]benzoic acid. 5th Communication: Factors affecting percutaneous absorption in rats. Arzneim-Forsch Drug Res 1997, 47: 270-5.
24. Mizojiri, K., Okabe, H., Sugeno, K., Esumi, Y., Takaichi, M., Tsutsumi, S., Harada, T., Miyoshi, R., Inaba, A. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl) carbamoyl]benzoic acid. 2nd Communication: Absorption, distribution and excretion after single and consecutive subcutaneous administration in rats. Arzneim-Forsch Drug Res 1997, 47: 195-200.
25. Mizojiri, K., Okabe, H., Sugeno, K., Esumi, Y., Takaichi, M., Harada, T., Seki, H., Inaba, A. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl]benzoic acid. 3rd Communication: Placental transfer and excretion into milk in rats. Arzneim-Forsch Drug Res 1997, 47: 201-8.
26. Mizojiri, K., Okabe, H., Sugeno, K. et al. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2- naphthyl)carbamoyl]benzoic acid. 4th Communication: Absorption, metabolism, excretion and plasma protein binding in various animals and man. Arzneim-Forsch Drug Res 1997, 47: 259-69.
27. Ohno, R., Takeshita, S.A., Miyawaki, S., Hiraoka, A., Ino, M., Naoe, T., Shudo, K., Ueda, R. Treatment of acute promyelocytic leukemia (APL) which has relapsed after all-trans retinoic acid (ATRA) induced remission with a new synthetic retinoid, AM-80. Proc Am Soc Clin Oncol (ASCO) 1996, 15: Abst 1062.
28. Kitamura, K., Kiyoi, H., Yoshida, H., Tobita, T., Takeshita, A., Ohno, R., Naoe, T. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: Clinical and basic studies for the next generation. Cancer Chemother Pharmacol 1997, 40(Suppl.) S36-41.
29. Takeuchi, M., Yano, T., Omoto, E., Takahashi, K., Kibata, M., Shudo, K., Ueda, R., Ohno, R., Harada, M. Re-induction of complete remission with a new synthetic retinoid, Am-80, for relapse of acute promyelocytic leukaemia previously treated with alltrans retinoic acid. Br J Haematol 1997, 97: 137-40.
30. Tobita, T., Takeshita, A., Kitamura, K. et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 1997, 90: 967-73.
31. Takeuchi, M., Yano, T., Omoto, E., Takahashi, K., Kibata, M., Shudo, K., Harada, M., Ueda, R., Ohno, R. Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80. Leuk Lymphoma 1998, 31: 441-51.
32. Shinjo, K., Takeshita, A., Ohnishi, K. et al. Good prognosis of patients with acute promyelocytic leukemia who achieved second complete remission (CR) with a new retinoid, Am80, after relapse from CR induced by all-trans retinoic acid. Int J Hematol 2000, 72: 470-3.